תאריך רישום: November 29, 2022

מסלול הגשה: מולקולה חדשה

יצרן: BAUSCH & LOMB INCORPORATED, USA

בעל רישום: FISCHER PHARMA RX LTD

S01EE06 :ATC Code

תאריך רישום: January 3, 2022

מסלול הגשה: מולקולה חדשה

יצרן: CATALENT PHARMA SOLUTIONS, LLC, USA

בעל רישום: PROGENETICS LTD, ISRAEL

A11CC06 :ATC Code

תאריך רישום: November 29, 2022

מסלול הגשה: מולקולה חדשה

יצרן: BAUSCH & LOMB INCORPORATED, USA

בעל רישום: FISCHER PHARMA RX LTD

S01AE08 :ATC Code

תאריך רישום: June 27, 2023

מסלול הגשה: מולקולה חדשה

יצרן: BIOGEN INTERNATIONAL GMBH, SWITZERLAND

בעל רישום: EISAI ISRAEL LTD., ISRAEL

N06DX04 :ATC Code

 1 INDICATIONS AND USAGE LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

תאריך רישום: July 15, 2014

מסלול הגשה: מולקולה חדשה

יצרן: MERCK SHARP & DOHME B.V, THE NETHERLANDS

בעל רישום: ORGANON PHARMA ISRAEL LTD., ISRAEL

A11CC05 :ATC Code

THERAPEUTIC INDICATIONS AND USAGE FOSAVANCE® 70 mg/ 5600 IU TABLETS are indicated for: 1.1 Treatment of Osteoporosis in Postmenopausal Women For the treatment of osteoporosis, FOSAVANCE 70 MG/ 5600 IU TABLETS increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Treatment to Increase Bone Mass in Men with Osteoporosis FOSAVANCE 70 MG/ 5600 IU TABLETS is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.2)]. 1.2 Important Limitations of Use FOSAVANCE 70 MG/ 5600 IU TABLETS alone should not be used to treat vitamin D deficiency. The optimal duration of use has not been determined. The safety and effectiveness of FOSAVANCE 70 MG/ 5600 IU TABLETS for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

תאריך רישום: January 20, 1999

מסלול הגשה: מולקולה חדשה

יצרן: NOVO NORDISK A/S, DENMARK

בעל רישום: NOVO NORDISK LTD., ISRAEL

G03AA05 :ATC Code

4.1 Therapeutic indications Hormone Replacement Therapy (HRT) for oestrogen deficiency symptoms in women with more than one year after menopause. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. The experience treating women older than 65 years is limited.